Skip to main content
SpringerLink
Log in

Recent Advances in Nanoformulation-Based Intranasal Delivery of Bioactive Compounds and Biologics for Neurodegenerative Disorders (NDDs)

  • Conference paper
  • First Online:
Recent Trends in Nanotechnology for Sustainable Living and Environment (ICON-NSLE 2022)

Part of the book series: Lecture Notes in Mechanical Engineering ((LNME))

  • 106 Accesses

Abstract

As a result of the catastrophic rise in the incidence and transmission of neurodegenerative disorders (CNS), around 24.3% of the world's population was predicted to have Alzheimer's disease (AD), or Parkinson's disease (PD) in 2015. A wide range of drugs have been created over the last three to four decades to address different neurological conditions. Many of the drugs listed for treating cerebral diseases cannot reach the brain because of the blood–brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB), which are biological barriers to the brain. As a result, their effectiveness in treating cerebral disorders is reduced. Phytopharmaceuticals are generally preferred over chemically generated medicines because to their slightly greater patient compliance and lower negative effects. However, special administration techniques that have the ability to drastically change the ADME properties of these potential drugs are required for them to reach their maximum therapeutic index. The intranasal medication delivery channel via an olfactory neural pathway has successfully demonstrated the high efficacy and minimal side effects of the direct targeting technique for the delivery of drugs in the brain in neurological disorders. There are numerous natural compounds that have been studied for the treatment of neuronal disorders and their effective delivery to the targeted site of the brain, including crude extracts of Curcuma longa, Centella Asiatica, Gingko Biloba, Theobroma cacao, Withania somnifera, Bacopa monnieri, etc. and pure substances like—Bilobalide, Quercetin, (-)-Epigal. In comparison to their conventional forms, the therapeutic efficacy, stability, and release kinetics of these extracts/phytocompounds’ nanoformulations are produced and evaluated. And in mouse models of AD produced by commercial medicines, the results of these nanoformulations showed considerably greater neuroprotective efficacy. This shows that the formulations based on natural compounds have the potential to improve the pathological condition of AD and may be pursued as a prospective candidate for clinical research to determine its effectiveness in humans.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ravishankar B, Shukla VJ (2007) Indian systems of medicine: a brief profile, (in eng). Afr J Tradit Complement Altern Med 4(3):319–337

    CAS  Google Scholar 

  2. Singh M, Singh S, Rachana R (2017) Development, characterization and cytotoxicity evaluation of Gingko biloba extract (EGB761) loaded microemulsion for intra-nasal application. J Appl Pharm Sci 7:024–034

    Google Scholar 

  3. Ramteke RS, Patil PD, Thakar AB (2016) Efficacy of Nasya (nasal medication) in coma: a case study, (in eng). Anc Sci Life 35(4):232–235

    Google Scholar 

  4. Rastogi S, Iqbal Z (2019) Pharmacovigilance concerns of Nasya (Intranasal drug delivery) practices in Ayurveda

    Google Scholar 

  5. Farooqui AA, Farooqui T, Madan A, Ong JH, Ong WY (2018) Ayurvedic Medicine for the Treatment of Dementia: Mechanistic Aspects, (in eng). Evid Based Complement Alternat Med 2018:2481076

    Google Scholar 

  6. Ekor M (2014) The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety, (in eng). Front Pharmacol 4:177

    Google Scholar 

  7. Keller L-A, Merkel O, Popp A (2022) Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv Transl Res 12(4):735–757

    Google Scholar 

  8. Durães F, Pinto M, Sousa E (2018) Old drugs as new treatments for neurodegenerative diseases. Pharmaceuticals 11(2):44

    Google Scholar 

  9. Engelhardt B, Sorokin L (2009) The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction, (in eng). Semin Immunopathol 31(4):497–511

    Google Scholar 

  10. Jaiswal YS, Williams LL (2017) A glimpse of Ayurveda—the forgotten history and principles of Indian traditional medicine, (in eng). J Tradit Complement Med 7(1):50–53

    Google Scholar 

  11. Islam SU, Shehzad A, Ahmed MB, Lee YS (2020) Intranasal delivery of nanoformulations: a potential way of treatment for neurological disorders, (in eng). Molecules 25(8)

    Google Scholar 

  12. Dias DA, Urban S, Roessner U (2012) A historical overview of natural products in drug discovery, (in eng). Metabolites 2(2):303–336

    CAS  Google Scholar 

  13. WHO (2022) Maximizing potential of traditional medicines through modern science and technology. WHO establishes the Global Centre for Traditional Medicine in India

    Google Scholar 

  14. Forni C et al (2019) Beneficial role of phytochemicals on oxidative stress and age-related diseases, (in eng). Biomed Res Int 2019:8748253

    Google Scholar 

  15. Jindal D, Rani V (2022) In Silico studies of phytoconstituents from piper longum and ocimum sanctum as ACE2 and TMRSS2 inhibitors: strategies to combat COVID-19, (in eng). Appl Biochem Biotechnol 1–18

    Google Scholar 

  16. Koeberle A, Werz O (2014) Multi-target approach for natural products in inflammation. Drug Discov Today 19

    Google Scholar 

  17. Fini L et al (2007) Annurca apple polyphenols have potent demethylating activity and can reactivate silenced tumor suppressor genes in colorectal cancer cells, (in eng). J Nutr 137(12):2622–2628

    CAS  Google Scholar 

  18. Kaurinovic B, Vastag G (2019) Flavonoids and phenolic acids as potential natural antioxidants

    Google Scholar 

  19. Singh A, Kukreti R, Saso L, Kukreti S (2019) Oxidative stress: a key modulator in neurodegenerative diseases, (in eng). Molecules 24(8)

    Google Scholar 

  20. Joy D et al (2022) Development of microneedle patch loaded with bacopa monnieri solid lipid nanoparticles for the effective management of Parkinson’s disease, (in eng). Bioinorg Chem Appl 2022:9150205

    Google Scholar 

  21. Limpeanchob N, Jaipan S, Rattanakaruna S, Phrompittayarat W, Ingkaninan K (2008) Neuroprotective effect of Bacopa monnieri on beta-amyloid-induced cell death in primary cortical culture. J Ethnopharmacol 120(1):112–117

    Google Scholar 

  22. Kashyap VK, Peasah-Darkwah G, Dhasmana A, Jaggi M, Yallapu MM, Chauhan SC (2022) Withania somnifera: progress towards a pharmaceutical agent for immunomodulation and cancer therapeutics. Pharmaceutics 14(3):611

    CAS  Google Scholar 

  23. Chinembiri TN, Gerber M, du Plessis LH, du Preez JL, Hamman JH, du Plessis J (2017) Topical delivery of withania somnifera crude extracts in niosomes and solid lipid nanoparticles, (in eng). Pharmacogn Mag 13(Suppl 3):S663–S671

    Google Scholar 

  24. Sugimoto N, Miwa S, Hitomi Y, Nakamura H, Tsuchiya H, Yachie A (2014) Theobromine, the primary methylxanthine found in Theobroma cacao, prevents malignant glioblastoma proliferation by negatively regulating phosphodiesterase-4, extracellular signal-regulated kinase, Akt/mammalian target of rapamycin kinase, and nuclear factor-kappa B, (in eng). Nutr Cancer 66(3):419–423

    CAS  Google Scholar 

  25. Vergallo C (2020) Nutraceutical vegetable oil nanoformulations for prevention and management of diseases. Nanomaterials 10(6):1232

    CAS  Google Scholar 

  26. Manisha Singh RK, Rajput R, Mathur G (2017) Evaluating the therapeutic efficiency and drug targeting ability of alkaloids present in Rauwolfia serpentina. Green Pharmacy 11(3)

    Google Scholar 

  27. Mishra A et al (2021) Neuroprotective potential of chrysin: mechanistic insights and therapeutic potential for neurological disorders. Molecules 26(21):6456

    CAS  Google Scholar 

  28. Concetta Scuto M et al (2019) Curcumin, hormesis and the nervous system, (in eng). Nutrients 11(10)

    Google Scholar 

  29. Veerendra Kumar MH, Gupta YK (2003) Effect of Centella asiatica on cognition and oxidative stress in an intracerebroventricular streptozotocin model of Alzheimer's disease in rats, (in eng). Clin Exp Pharmacol Physiol 30(5–6):336–342

    Google Scholar 

  30. Imenshahidi M, Hosseinzadeh H (2006) The pharmacological effects of Salvia species on the central nervous system. Phytother Res: PTR 20:427–37

    Google Scholar 

  31. López V, Martín S, Gómez-Serranillos MP, Carretero ME, Jäger AK, Calvo MI (2009) Neuroprotective and neurological properties of Melissa officinalis, (in eng). Neurochem Res 34(11):1955–1961

    Google Scholar 

  32. Guo C et al (2020) Bilobalide reversibly modulates blood-brain barrier permeability through promoting adenosine A1 receptor-mediated phosphorylation of actin-binding proteins. Biochem Biophys Res Commun 526(4):1077–1084

    Google Scholar 

  33. Mähler A et al (2013) Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?, (in eng). Epmaj 4(1):5

    Google Scholar 

  34. Wu Y et al (2018) Stilbenes from veratrum maackii regel protect against ethanol-induced DNA damage in mouse cerebellum and cerebral cortex, (in eng). ACS Chem Neurosci 9(7):1616–1624

    CAS  Google Scholar 

  35. Chooi Ling L et al (2022) Precision and advanced nano-phytopharmaceuticals for therapeutic applications. Nanomaterials 12

    Google Scholar 

  36. Mendoza N, Silva EME (2018) In: Asaduzzaman AT (ed) Introduction to phytochemicals: secondary metabolites from plants with active principles for pharmacological importance. In: Phytochemicals—Source of antioxidants and role in disease prevention [Internet]. IntechOpen, London

    Google Scholar 

  37. Yoo S, Kim K, Nam H, Lee D (2018) Discovering health benefits of phytochemicals with integrated analysis of the molecular network, chemical properties and ethnopharmacological evidence, (in eng). Nutrients 10(8)

    Google Scholar 

  38. Palermo M, Pellegrini N, FoglianoV (2014) The effect of cooking on phytochemical content in vegetables: a review. J Sci Food Agric 94

    Google Scholar 

  39. Coutinho AE, Chapman KE (2011) The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights, (in eng). Mol Cell Endocrinol 335(1):2–13

    CAS  Google Scholar 

  40. Dixit T, Tiwari A, Bose S, Kulkarni H, Suthar J, Ravindran S (2021) Metabolism of phytochemicals. Drug Metab

    Google Scholar 

  41. Gao S, Hu M (2010) Bioavailability challenges associated with development of anti-cancer phenolics, (in eng). Mini Rev Med Chem 10(6):550–567

    CAS  Google Scholar 

  42. Shindikar A, Singh A, Nobre M, Kirolikar S (2016) Curcumin and resveratrol as promising natural remedies with nanomedicine approach for the effective treatment of triple negative breast cancer, (in eng). J Oncol 2016:9750785

    Google Scholar 

  43. Strimpakos AS, Sharma RA (2008) Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials, (in eng). Antioxid Redox Signal 10(3):511–545

    CAS  Google Scholar 

  44. Goel A, Jhurani S, Aggarwal BB (2008) Multi-targeted therapy by curcumin: how spicy is it?, (in eng). Mol Nutr Food Res 52(9):1010–1030

    CAS  Google Scholar 

  45. Maia L, de Mendonça A (2002) Does caffeine intake protect from Alzheimer’s disease?, (in eng). Eur J Neurol 9(4):377–382

    CAS  Google Scholar 

  46. Mandel S, Youdim MB (2004) Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases, (in eng). Free Radic Biol Med 37(3):304–317

    CAS  Google Scholar 

  47. Reznichenko L et al (2006) Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer’s disease, (in eng). J Neurochem 97(2):527–536

    CAS  Google Scholar 

  48. Weinreb O, Mandel S, Amit T, Youdim MB (2004) Neurological mechanisms of green tea polyphenols in Alzheimer’s and Parkinson’s diseases, (in eng). J Nutr Biochem 15(9):506–516

    CAS  Google Scholar 

  49. Khan M (2017) The novel drug delivery system. World J Pharm Pharm Sci 6:477–487

    Google Scholar 

  50. Devi VK, Jain N, Valli KS (2010) Importance of novel drug delivery systems in herbal medicines, (in eng). Pharmacogn Rev 4(7):27–31

    Google Scholar 

  51. Mikušová V, Mikuš P (2021) Advances in Chitosan-based nanoparticles for drug delivery, (in eng). Int J Mol Sci 22(17)

    Google Scholar 

  52. Blanco E, Shen H, Ferrari M (2015) Principles of nanoparticle design for overcoming biological barriers to drug delivery, (in eng). Nat Biotechnol 33(9):941–951

    CAS  Google Scholar 

  53. Wermeling DP (2006) Compositions and methods for intranasal delivery of tricyclic cannabinoids. US

    Google Scholar 

  54. Huestis MA (2005) Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol, (in eng). Handb Exp Pharmacol 168:657–690

    CAS  Google Scholar 

  55. Sathya S, Shanmuganathan B, Devi KP (2020) Deciphering the anti-apoptotic potential of α-bisabolol loaded solid lipid nanoparticles against Aβ induced neurotoxicity in Neuro-2a cells. Colloids SurfS B: Biointerfaces 190:110948

    Google Scholar 

  56. Pinheiro RGR et al (2020) Quercetin lipid nanoparticles functionalized with transferrin for Alzheimer's disease. Eur J Pharm Sci 148:105314

    Google Scholar 

  57. Mathew A et al (2012) Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer’s disease. PLoS ONE 7(3):e32616

    CAS  Google Scholar 

  58. Pinheiro RGR et al (2020) RVG29-Functionalized Lipid Nanoparticles for Quercetin Brain Delivery and Alzheimer’s Disease. Pharm Res 37(7):139

    Google Scholar 

  59. Cano A et al (2019) Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer’s disease mice model, (in eng). J Control Release 301:62–75

    CAS  Google Scholar 

  60. Zhao Y et al (2020) Polymeric nanoparticles-based brain delivery with improved therapeutic efficacy of Ginkgolide B in Parkinson’s disease, (in eng). Int J Nanomedicine 15:10453–10467

    Google Scholar 

  61. Xue Y, Wang N, Zeng Z, Huang J, Xiang Z, Guan Y-Q (2020) Neuroprotective effect of chitosan nanoparticle gene delivery system grafted with acteoside (ACT) in Parkinson’s disease models. J Mater Sci Technol 43:197–207

    Google Scholar 

  62. Tan JPK et al (2019) Effective encapsulation of apomorphine into biodegradable polymeric nanoparticles through a reversible chemical bond for delivery across the blood–brain barrier. Nanomedicine: Nanotechnol, Biol Med 17:236–245

    Google Scholar 

  63. Wang ZH, Wang ZY, Sun CS, Wang CY, Jiang TY, Wang SL (2010) Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain, (in eng). Biomaterials 31(5):908–915

    CAS  Google Scholar 

  64. Meng Q et al (2018) Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer’s disease, (in eng). Int J Nanomedicine 13:705–718

    CAS  Google Scholar 

  65. Lohan S, Raza K, Mehta SK, Bhatti GK, Saini S, Singh B (2017) Anti-Alzheimer’s potential of berberine using surface decorated multi-walled carbon nanotubes: a preclinical evidence, (in eng). Int J Pharm 530(1–2):263–278

    CAS  Google Scholar 

  66. Kheradmand E, Hajizadeh Moghaddam A, Zare M (2018) Neuroprotective effect of hesperetin and nano-hesperetin on recognition memory impairment and the elevated oxygen stress in rat model of Alzheimer's disease, (in eng). Biomed Pharmacother 97:1096–1101

    Google Scholar 

  67. Shea TB, Ortiz D, Nicolosi RJ, Kumar R, Watterson AC (2005) Nanosphere-mediated delivery of vitamin E increases its efficacy against oxidative stress resulting from exposure to amyloid beta, (in eng). J Alzheimers Dis 7(4):297–301

    CAS  Google Scholar 

  68. Esteves M et al (2015) Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model for Parkinson's disease, (in English). Frontiers Aging Neurosci Original Research 7

    Google Scholar 

  69. Vedagiri A, Thangarajan S (2016) Mitigating effect of chrysin loaded solid lipid nanoparticles against Amyloid β25-35 induced oxidative stress in rat hippocampal region: an efficient formulation approach for Alzheimer’s disease, (in eng). Neuropeptides 58:111–125

    CAS  Google Scholar 

  70. Yin T, Yang L, Liu Y, Zhou X, Sun J, Liu J (2015) Sialic acid (SA)-modified selenium nanoparticles coated with a high blood-brain barrier permeability peptide-B6 peptide for potential use in Alzheimer’s disease, (in eng). Acta Biomater 25:172–183

    CAS  Google Scholar 

  71. Ferro C, Florindo HF, Santos HA (2021) Selenium nanoparticles for biomedical applications: from development and characterization to therapeutics. Adv Healthcare Mater 10(16):2100598

    CAS  Google Scholar 

  72. Bhatt PC, Verma A, Al-Abbasi FA, Anwar F, Kumar V, Panda BP (2017) Development of surface-engineered PLGA nanoparticulate-delivery system of Tet1-conjugated nattokinase enzyme for inhibition of Aβ(40) plaques in Alzheimer’s disease, (in eng). Int J Nanomedicine 12:8749–8768

    CAS  Google Scholar 

  73. Shaji J, Patole V (2008) Protein and Peptide drug delivery: oral approaches, (in eng). Indian J Pharm Sci 70(3):269–277

    Google Scholar 

  74. Vuppaladhadiam L, Ehsan C, Akkati M, Bhargava A (2020) Corticotropin-releasing factor family: a stress hormone-receptor system's emerging role in mediating sex-specific signaling, (in eng). Cells 9(4)

    Google Scholar 

  75. Serhan A, Boddeke E, Kooijman R (2019) Insulin-like growth factor-1 Is neuroprotective in aged rats with ischemic stroke, (in eng). Front Aging Neurosci 11:349

    CAS  Google Scholar 

  76. Meredith ME, Salameh TS, Banks WA (2015) Intranasal delivery of proteins and peptides in the treatment of neurodegenerative diseases. AAPS J 17(4):780–787

    Google Scholar 

  77. Iliff JJ et al (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including Amyloid β. Sci Transl Med 4(147):147ra111–147ra111

    Google Scholar 

  78. Danielyan L et al (2020) Cell motility and migration as determinants of stem cell efficacy. eBioMedicine 60

    Google Scholar 

  79. Zhang N, Yin Y, Xu SJ, Chen WS (2008) 5-Fluorouracil: mechanisms of resistance and reversal strategies, (in eng). Molecules 13(8):1551–1569

    CAS  Google Scholar 

  80. Ul Hassan A, Hassan G, Rasool Z (2009) Role of stem cells in treatment of neurological disorder, (in eng). Int J Health Sci (Qassim) 3(2):227–33

    Google Scholar 

  81. Hayes MW, Fung VS, Kimber TE, O’Sullivan JD (2019) Updates and advances in the treatment of Parkinson disease. Med J Aust 211(6):277–283

    Google Scholar 

  82. Jamebozorgi K et al (2019) Cellular and molecular aspects of Parkinson treatment: future therapeutic perspectives. Mol Neurobiol 56(7):4799–4811

    Google Scholar 

  83. Danielyan L et al (2011) Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease, (in eng). Rejuvenation Res 14(1):3–16

    CAS  Google Scholar 

  84. Li YH et al (2017) Fasudil Enhances therapeutic efficacy of neural stem cells in the mouse model of MPTP-Induced Parkinson’s disease, (in eng). Mol Neurobiol 54(7):5400–5413

    CAS  Google Scholar 

  85. Simon C et al (2019) Deciduous DPSCs Ameliorate MPTP-mediated neurotoxicity, sensorimotor coordination and olfactory function in Parkinsonian mice. Int J Mol Sci 20(3):568

    CAS  Google Scholar 

  86. Danielyan L et al (2014) Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer's and Parkinson's disease. Cell Transplant 23(1_suppl):123–139

    Google Scholar 

  87. Salama M et al (2017) Effect of intranasal stem cell administration on the nigrostriatal system in a mouse model of Parkinson’s disease, (in eng). Exp Ther Med 13(3):976–982

    CAS  Google Scholar 

  88. McDonald CA et al (2019) Intranasal delivery of mesenchymal stromal cells protects against neonatal hypoxic-ischemic brain injury. Int J Mol Sci 20(10):2449

    Google Scholar 

  89. Duncan T, Valenzuela M (2017) Alzheimer's disease, dementia, and stem cell therapy, (in eng). Stem Cell Res Ther 8(1):111

    Google Scholar 

  90. Mani S, Jindal D, Singh M (2022) Gene Therapy, a potential therapeutic tool for neurological and neuropsychiatric disorders: applications, challenges and future prospective, (in eng). Curr Gene Ther

    Google Scholar 

  91. Mita T et al (2015) Conditioned medium from the stem cells of human dental pulp improves cognitive function in a mouse model of Alzheimer’s disease, (in eng). Behav Brain Res 293:189–197

    CAS  Google Scholar 

  92. Perets N et al (2019) Golden exosomes selectively target brain pathologies in neurodegenerative and neurodevelopmental disorders, (in eng). Nano Lett 19(6):3422–3431

    CAS  Google Scholar 

  93. Harach T et al (2017) Administrations of human adult ischemia-tolerant mesenchymal stem cells and factors reduce amyloid beta pathology in a mouse model of Alzheimer’s disease, (in eng). Neurobiol Aging 51:83–96

    CAS  Google Scholar 

  94. Merkus FW, Verhoef JC, Schipper NG, Marttin E (1998) Nasal mucociliary clearance as a factor in nasal drug delivery, (in eng). Adv Drug Deliv Rev 29(1–2):13–38

    CAS  Google Scholar 

  95. Kumar M, Pathak K, Misra A (2008) Formulation and characterization of nanoemulsion-based drug delivery system of risperidone. Drug Dev Ind Pharm 35:387–395

    Google Scholar 

  96. Boddupalli BM, Mohammed ZN, Nath RA, Banji D (2010) Mucoadhesive drug delivery system: an overview, (in eng). J Adv Pharm Technol Res 1(4):381–387

    CAS  Google Scholar 

  97. Kita K, Dittrich C (2011) Drug delivery vehicles with improved encapsulation efficiency: taking advantage of specific drug-carrier interactions. Expert Opin Drug Deliv 8:329–42

    Google Scholar 

  98. Rueda F, Cruz L (2016) Targeting the Brain with Nanomedicine. Curr Pharm Des 23

    Google Scholar 

Download references

Acknowledgements

The research group is thankful to Jaypee Institute of Information Technology for providing the facility to carry out the work.

Author information

Authors and Affiliations

  1. Department of Biotechnology, Jaypee Institute of Information Technology, Sector-62, Noida, 201307, Uttar Pradesh, India

    Manisha Singh & Divya Jindal

Authors
  1. Manisha Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Divya Jindal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manisha Singh .

Editor information

Editors and Affiliations

  1. Department of Chemical Engineering, Indian Institute of Technology Kharagpur, Kharagpur, West Bengal, India

    Rabibrata Mukherjee

  2. Institute of Inorganic and Structural Chemistry, Heinrich Heine University, Düsseldorf, Germany

    Christoph Janiak

  3. Linköping University, Linköping, Sweden

    Ziyauddin Khan

  4. Department of Chemical Engineering, Birla Institute of Technology and Science, Pilani, Rajasthan, India

    Somak Chatterjee

  5. Department of Chemical Engineering, Birla Institute of Technology and Science, Pilani, Rajasthan, India

    Banasri Roy

  6. Department of Chemical Engineering, Birla Institute of Technology and Science, Pilani, Rajasthan, India

    Sarbani Ghosh

  7. Department of Chemical Engineering, Birla Institute of Technology and Science, Pilani, Rajasthan, India

    Krishna Etika

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this paper

Check for updates. Verify currency and authenticity via CrossMark

Cite this paper

Singh, M., Jindal, D. (2023). Recent Advances in Nanoformulation-Based Intranasal Delivery of Bioactive Compounds and Biologics for Neurodegenerative Disorders (NDDs). In: Mukherjee, R., et al. Recent Trends in Nanotechnology for Sustainable Living and Environment. ICON-NSLE 2022. Lecture Notes in Mechanical Engineering. Springer, Singapore. https://doi.org/10.1007/978-981-99-3386-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-981-99-3386-0_6

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-99-3385-3

  • Online ISBN: 978-981-99-3386-0

  • eBook Packages: EngineeringEngineering (R0)

Publish with us

Policies and ethics

Search

Navigation